SeaStar Medical Holding Corporation (ICU) is advancing medical technology focused on mitigating the adverse effects of hyperinflammation on vital organs. The company specializes in creating and commercializing extracorporeal therapies that specifically target effector cells responsible for systemic inflammation, which often leads to direct tissue damage and the secretion of pro-inflammatory cytokines, triggering imbalanced immune responses.
Core Business and Technology
SeaStar Medical's core business revolves around innovative treatments designed to alleviate intense inflammatory responses seen in various medical conditions. Their primary product offerings include advanced renal therapy systems that aim to reduce the impact of cytokine storms, often observed in severe cases of infections and autoimmune diseases. These extracorporeal therapies involve treating blood outside the body to remove harmful substances like pro-inflammatory cytokines.
Clinical Achievements and R&D
One of the company’s notable achievements includes successful clinical trials demonstrating the efficacy of their therapies in reducing inflammation and improving patient outcomes. SeaStar Medical is currently engaged in several research and development projects to expand the application of their therapies across multiple medical disciplines. The company collaborates with various healthcare providers and research institutions to enhance their product development and distribution.
Financial Position and Strategic Partnerships
SeaStar Medical Holding Corp is strategically positioned with partnerships that enhance their research capabilities and product distribution. The company is committed to advancing its technology through continuous innovation and maintaining strong relationships with healthcare providers and patients. As of October 25, 2024, the stock price of SeaStar Medical Holding Corporation (ICU) is $3.624, with a market cap of approximately $15.0 million.
